Highlights from ASCO 2011

While there weren’t new blockbuster announcements for colorectal cancer this year at the American Society for Clinical Oncology’s (ASCO) Annual Meeting, there was plenty of focus on making what we already have work better and on choosing the patients who will benefit the most from…

Read Full Post

Personalizing Personalized Medicine

On Monday, April 25th, Fight Colorectal Cancer held a free patient webinar that tackled the somewhat complex but fascinating topic of personalized medicine. Personalized medicine is what the cancer community calls treatments that are tailored to each patient’s genetic makeup. It is the future of…

Read Full Post

Commercial Test for BRAF Gene Available

Clarient Inc. announced the launch of a commercially available test for the BRAF mutation in colorectal cancer.  The test detects mutations in colorectal cancer tumor tissue. In a recent study, patients with mutated BRAF did not respond to treatment with two drugs that block epidermal…

Read Full Post

Preventive Measures Reduce Rash from Vectibix

Nearly all patients who are treated with Vectibix™ (panitumumab) will develop an itchy skin rash that looks something like acne.  However, treating the rash preemptively  before it appears reduces its severity and lengthens the time before more serious rash appears. During the STEPP (Skin Toxicity…

Read Full Post